Floatz logo

ADUCANUMAB

Cognitive Dysfunction

Biogenmonoclonal_antibodyPhase 2Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

150 Active assets in the Cognitive Dysfunction cohort.

Asset / SponsorPhaseRating
Ginkgo Biloba Extract
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Phase 4BBB
Rivastigmine
Singapore General Hospital
Phase 4BBB
Nicotine
University of Southern California
Phase 2BBB
Oxybutynin
University of Alberta
Phase 4BBB
Seroquel®
Emory University
Phase 4BB

View all 50 →

Same molecule, other indications

ADUCANUMAB is also rated in:

Alzheimer diseaseDormant
CCC
Indicative ·
55 / 100
View asset →
Mild Cognitive Impairment (MCI)Dormant
CCC
Indicative ·
52 / 100
View asset →
Alzheimer disease type 1Dormant
C
Indicative ·
38 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →